Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis
Crossref DOI link: https://doi.org/10.1007/s00228-024-03620-w
Published Online: 2024-02-01
Published Print: 2024-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yu, Zhuchen
Xu, Fei
Zou, Juntao
Text and Data Mining valid from 2024-02-01
Version of Record valid from 2024-02-01
Article History
Received: 14 October 2023
Accepted: 4 January 2024
First Online: 1 February 2024
Declarations
:
: The authors declare no competing interests.